Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Mapp Gets U.S. Funds To Develop Ebola Drug
by Rick Mullin
September 8, 2014
| A version of this story appeared in
Volume 92, Issue 36
The Department of Health & Human Services has signed a $24.9 million, 18-month contract with Mapp Biopharmaceutical to support the development and manufacturing of ZMapp, an experimental drug that has been given to some Ebola patients. Under the contract, Mapp will manufacture a small amount of the drug to demonstrate safety and efficacy in humans. Mapp will also work with HHS’s Biomedical Advanced Research & Development Authority to improve the manufacturing process for the drug, which is a combination of three monoclonal antibodies grown in tobacco plants. It is currently in extremely short supply.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X